Eli Lilly and Company (LLY)

NYQ – Real vaqt narxi. Valyuta: USD

1225.58

+10.56 (0.87%)

Bozor ochiq: Aug 12, 2026, 11:51 AM EDT

1218.00

+2.98 (0.25%)

Oldingi bozordan keyin: Aug 11, 2026, 7:58 PM EDT

10.08.2026

3 Beaten-Down Healthcare Stocks to Buy in August

Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.

10.08.2026

UK green lights Lilly's obesity pill

The British medicines ‌regulator on Monday authorised Eli ⁠Lilly's pill Foundayo for weight management and type 2 ‌diabetes, ⁠becoming Europe's first country to ⁠do so.

10.08.2026

Nvidia, Eli Lilly, and Disney Show It's Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now.

09.08.2026

Top 50 High-Quality Dividend Growth Stocks For August 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. The universe delivered a 10.44% YTD return through July, closely matching SPY but trailing SCHD, with several individual stocks significantly outperforming. Currently, 40 stocks in the universe offer a forward return estimate of at least 10%, with 25 appearing potentially undervalued based on free cash flow analysis.

08.08.2026

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising.

08.08.2026

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly and Company NYSE: LLY reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance.

07.08.2026

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly should request approval for retatrutide early next year. This medicine could help the company expand the weight loss market.

Videolar

05.08.2026

Negative

Wednesday's Final Takeaways: GOOGL AI Chief Leaves, GLP-1 Boosts LLY

05.08.2026

Positive

Market Close: Stock Rally Fades, Job Growth Weakens, Strong Earnings Boost Eli Lilly 8-5-2026

05.08.2026

Positive

Inside Out: LLY and the Future of Weight Loss Drugs

Press-relizlar

05.08.2026

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAAP basis.

03.08.2026

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test. Olomorasib is an investigational, potent and highly selective next-generation inhibitor of KRAS G12C.

Eli Lilly and Company (LLY)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Eli Lilly and Company (LLY)